Suma Krishnan - Jan 17, 2023 Form 4 Insider Report for Krystal Biotech, Inc. (KRYS)

Signature
/s/ Suma Krishnan
Stock symbol
KRYS
Transactions as of
Jan 17, 2023
Transactions value $
-$4,039,744
Form type
4
Date filed
1/19/2023, 04:44 PM
Previous filing
Jan 5, 2023
Next filing
Feb 28, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRYS Common Stock Sale -$1.66M -20.6K -1.21% $80.70 1.68M Jan 17, 2023 Direct F1, F2
transaction KRYS Common Stock Sale -$96.5K -1.19K -0.07% $81.41 1.68M Jan 17, 2023 Direct F1, F3
transaction KRYS Common Stock Sale -$28.5K -345 -0.02% $82.72 1.68M Jan 17, 2023 Direct F1, F4
transaction KRYS Common Stock Sale -$1.66M -20.6K -1.17% $80.70 1.74M Jan 17, 2023 By Spouse F2, F5, F6, F7
transaction KRYS Common Stock Sale -$96.5K -1.19K -0.07% $81.41 1.74M Jan 17, 2023 By Spouse F3, F5, F6, F7
transaction KRYS Common Stock Sale -$28.6K -346 -0.02% $82.71 1.74M Jan 17, 2023 By Spouse F4, F5, F6, F7
transaction KRYS Common Stock Sale -$165K -2.05K -0.12% $80.75 1.68M Jan 18, 2023 Direct F1, F8
transaction KRYS Common Stock Sale -$65.6K -804 -0.05% $81.56 1.68M Jan 18, 2023 Direct F1, F9
transaction KRYS Common Stock Sale -$165K -2.05K -0.12% $80.75 1.74M Jan 18, 2023 By Spouse F5, F6, F7, F8
transaction KRYS Common Stock Sale -$65.5K -803 -0.05% $81.56 1.74M Jan 18, 2023 By Spouse F5, F6, F7, F9
holding KRYS Common Stock 90K Jan 17, 2023 By SMK Trust
holding KRYS Common Stock 50K Jan 17, 2023 By Krishnan Family Trust F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on July 15, 2022 and will terminate on July 15, 2023 and contemplates quarterly sales of 25,000 shares with a limit price of $80.00 per share.
F2 The transaction was executed in multiple trades ranging from $80.1300 to $81.1000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F3 The transaction was executed in multiple trades ranging from $81.1300 to $82.0600. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F4 The transaction was executed in multiple trades ranging from $82.3300 to $83.2500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F5 The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish Krishnan. The Rule 10b5-1 trading plan adopted by the Reporting Person's spouse started on July 15, 2022 and will terminate on July 15, 2023 and contemplates quarterly sales of 25,000 shares with a limit price of $80.00 per share.
F6 These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish Krishnan.
F7 Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person.
F8 The transaction was executed in multiple trades ranging from $80.3500 to $81.3300. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F9 The transaction was executed in multiple trades ranging from $81.3700 to $81.9200. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F10 Directly beneficially owned by the Krishnan Family Trust. The Reporting Person and her spouse are each joint beneficial owners of the trust with joint voting and investment control.